SLS Company Profile and Key Details

Q: Who are the executives of SLS?

Mr. Andrew ElnatanVice President and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & QualityMr. Jörg W. BreitkopfHead of Clinical OperationsMr. Robert M. FrancomanoSenior Vice President & Chief Commercial OfficerDr. Angelos M. Stergiou M.D., ScD h.c.Founder, Pres, Chief Executive Officer & DirectorMs. Barbara A. WoodExecutive Vice President, Gen. Counsel & Sec.Dr. Dragan Cicic M.D., MBASenior Vice President of Clinical Devel.Mr. John Thomas Burns CPASenior Vice President & Chief Financial OfficerMs. Barbara A. Wood Esq.Executive Vice President, Gen. Counsel & Corporation Sec.

NASDAQ : SLS

SELLAS Life Sciences Group

$4.67

-0.21-4.30%

At Close 4:00 PM

55.84

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

SELLAS Life Sciences Group, Inc. (SLS) stock declined over -4.30%, trading at $4.67 on NASDAQ, down from the previous close of $4.88. The stock opened at $4.88, fluctuating between $4.66 and $4.92 in the recent session.

Stock Snapshot

4.88

Prev. Close

665.2M

Market Cap

4.655

Day Low

-18.68

P/E Ratio

-0.25

EPS (TTM)

-1.24

Cash Flow per Share

4.88

Open

142.44M

Number of Shares

4.92

Day High

99.7%

Free Float in %

-0.25

Book Value

3.41M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 29, 2026	4.88	4.92	4.66	4.67	3.41M
Apr 28, 2026	4.82	4.92	4.72	4.88	3.26M
Apr 27, 2026	4.74	5.02	4.63	4.88	6.46M
Apr 23, 2026	4.75	4.82	4.61	4.64	4.06M
Apr 22, 2026	5.03	5.05	4.78	4.78	5.12M
Apr 21, 2026	5.06	5.11	4.86	5.03	4.28M
Apr 20, 2026	5.26	5.47	4.97	4.99	6.36M
Apr 17, 2026	5.10	5.24	4.85	5.22	5.83M
Apr 16, 2026	4.89	5.05	4.81	4.93	3.39M
Apr 14, 2026	4.85	4.95	4.74	4.86	3.31M
Apr 13, 2026	4.75	4.84	4.53	4.76	4.01M
Apr 10, 2026	5.03	5.10	4.73	4.76	3.91M
Apr 09, 2026	4.83	5.18	4.79	5.05	5.47M
Apr 08, 2026	4.79	4.92	4.72	4.86	4.06M
Apr 07, 2026	4.44	4.61	4.35	4.51	3.03M
Apr 06, 2026	4.24	4.66	4.20	4.53	5.25M
Apr 02, 2026	4.07	4.20	4.02	4.13	4.8M
Apr 01, 2026	4.33	4.36	4.12	4.21	4.68M
Mar 31, 2026	4.09	4.31	4.08	4.23	8.28M
Mar 30, 2026	4.40	4.40	3.95	4.01	8.54M

Contact Details

New York City, NY 10036

United States

https://www.sellaslifesciences.com 646 200 5278

About Company

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Stock Peers

ARGX

0.99+0.13%

argenx SE$776.02 REGN

-45.41-6.21%

Regeneron Pharmaceuticals, Inc.$686.36 UTHR

1.96+0.34%

United Therapeutics Corporation$571.07 MDGL

1.89+0.37%

Madrigal Pharmaceuticals, Inc.$518.58 VRTX

-6.9-1.60%

Vertex Pharmaceuticals Incorporated$423.24 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

1.27+0.39%

Praxis Precision Medicines, Inc.$323.19 ALNY

-0.92-0.30%

Alnylam Pharmaceuticals, Inc.$301.19 KRYS

-9.32-3.46%

Krystal Biotech, Inc.$259.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Frequently Asked Questions

What is the current SELLAS Life Sciences Group, Inc. (SLS) stock price?

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) stock price is $4.67 in the last trading session. During the trading session, SLS stock reached the peak price of $4.92 while $4.66 was the lowest point it dropped to. The percentage change in SLS stock occurred in the recent session was -4.3% while the dollar amount for the price change in SLS stock was - $0.21.

SLS's industry and sector of operation?

The NASDAQ listed SLS is part of Biotechnology industry that operates in the broader Healthcare sector. SELLAS Life Sciences Group, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SLS?

Mr. Andrew Elnatan
Vice President and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality
Mr. Jörg W. Breitkopf
Head of Clinical Operations
Mr. Robert M. Francomano
Senior Vice President & Chief Commercial Officer
Dr. Angelos M. Stergiou M.D., ScD h.c.
Founder, Pres, Chief Executive Officer & Director
Ms. Barbara A. Wood
Executive Vice President, Gen. Counsel & Sec.
Dr. Dragan Cicic M.D., MBA
Senior Vice President of Clinical Devel.
Mr. John Thomas Burns CPA
Senior Vice President & Chief Financial Officer
Ms. Barbara A. Wood Esq.
Executive Vice President, Gen. Counsel & Corporation Sec.

How SLS did perform over past 52-week?

SLS's closing price is 243.38% higher than its 52-week low of $1.36 where as its distance from 52-week high of $6.14 is -23.94%.

How many employees does SLS have?

Number of SLS employees currently stands at 15.

Link for SLS official website?

Official Website of SLS is: https://www.sellaslifesciences.com

How do I contact SLS?

SLS could be contacted at phone 646 200 5278 and can also be accessed through its website. SLS operates from Times Square Tower, New York City, NY 10036, United States.

How many shares of SLS are traded daily?

SLS stock volume for the day was 3.41M shares. The average number of SLS shares traded daily for last 3 months was 6.33M.

What is the market cap of SLS currently?

The market value of SLS currently stands at $665.20M with its latest stock price at $4.67 and 142.44M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	15
Beta	2.23
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	15
Beta	2.23
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

SLS Company Profile and Key Details

SELLAS Life Sciences Group

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook